Posts by: Joana Fernandes, PhD

Joana Fernandes, PhD

Joana brings more than 8 years of academic research and experience as well as Scientific writing and editing to her role as a Science and Research writer. She also served as a Postdoctoral Researcher at the Center for Neuroscience and Cell Biology in Coimbra, Portugal, where she also received her PhD in Health Science and Technologies, with a specialty in Molecular and Cellular Biology.

April 27, 2017April 27, 2017

Gilead Sciences Presents New Data on HCV, HBV Treatment with Harvoni

Hepatitis B, Hepatitis C, News

Harvoni (ledipasvir/sofosbuvir) may become a potential treatment for children with chronic hepatitis C virus (HCV) infection and adults with hepatitis B virus (HBV), according to results of two clinical trials ... Read more

March 9, 2017March 9, 2017

Baby Boomers at Risk of Hepatitis C Infection Aren’t Getting Tested, Despite Official Prodding

Hepatitis C, News

Despite official recommendations, most Americans born between 1945 and 1965 aren’t being tested for hepatitis C virus (HCV). That’s according to a new study, “Recent Hepatitis C Virus Testing Patterns Among Baby ... Read more

February 21, 2017February 21, 2017

‘Treat-All’ Medicaid Policy Improves Outcomes, Reduces Healthcare Costs in HCV

Hepatitis C, News

A restrictive Medicaid policy in many states limits hepatitis C virus (HCV) treatment to patients with severe disease, which leads to suboptimal treatment outcomes, high patient burden, and excessive costs. Now, ... Read more

December 22, 2016December 22, 2016

Combo of RNA Interference Therapies and Antiviral Agents Treat Hepatitis B in Early Study

Hepatitis B, News

Treatments combining Benitec Biopharma’s investigative agents — BB-101, BB-102 or BB-103 — with current standard of care may be a way of treating hepatitis B virus (HBV) infection, according to results obtained ... Read more

December 8, 2016December 8, 2016

Models Seen to Predict Transmission Risk of HCV and HIV Infection in Drug Users

Hepatitis C, News

Researchers developed mathematical models to predict the association between the transmission of HIV and hepatitis C virus (HCV) infection transmission among people who inject drugs. The findings obtained may help ... Read more

November 29, 2016November 29, 2016

Gilead Sciences Canada Recognized for Developing Harvoni as Hepatitis C Therapy

Hepatitis C, News

Gilead Sciences Canada has been awarded this year’s Prix Galien Canada–Innovative Product Award for the development of Harvoni (ledipasvir/sofosbuvir), a once-daily combination pill for the treatment of chronic genotype 1 hepatitis ... Read more

October 25, 2016October 25, 2016

Combo Anti-Viral Treatment for Chronic Hepatitis C Shows Efficacy in Phase 3 Studies

Hepatitis C, News

Top-line results from four global Phase 3 clinical studies (POLARIS-1, POLARIS-2, POLARIS-3, and POLARIS-4), led by Gilead Sciences, showed that the combination of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) — inhibitors of viral activity — can ... Read more